LAG-3 and PD-1 have been detected to be co-expressed on CD4+ and CD8+ TILs in preclinical mouse tumor models, suggesting that their co-blockade of the LAG-3 and PD-1 signaling pathways can enhance the proliferation of tumor-specific CD8+ T cells and cytokine release [16]. The gene discussed is LAG3; the disease is neoplasm.